TOKYO (Reuters) – Japan has selected three candidates for COVID-19 treatments to receive subsidies for clinical trials, the health ministry said on Tuesday.
The drugs are AstraZeneca Plc’s antibody treatment AZD7442, Shionogi & Co’s protease inhibitor S-217622, and Fujifilm Holding Corp’s antiviral favipiravir, known commercially as Avigan.
(Reporting by Rocky Swift; Editing by Clarence Fernandez)
